\-\ Texto\\:\\ \ \(0\)\
\-\ left\\ breast\\ distinctly\\ larger\\ than\\ the\\ right\\ breast\\.\\ \\ there\\ is\\ diffuse\\ erythema\\,\\ brawny\\ edema\\ and\\ peau\\ d\\â\\€\\™orange\\ covering\\ approximately\\ two\\-thirds\\ of\\ the\\ breast\\.\\ \\ no\\ distinct\\ breast\\ masses\\ or\\ nipple\\ discharge\\.\\ \\ multiple\\ mobile\\ congruent\\ masses\\ were\\ palpated\\ in\\ the\\ left\\ axilla\\.\\ normal\\ right\\ breast\\ and\\ axilla\\.\\ \\ left\\ supraclavicular\\ palpable\\ mass\\.\ \(0\)\
\-\ the\\ patient\\ is\\ currently\\ being\\ treated\\ with\\ neoadjuvant\\ chemotherapy\\.\\ \\ this\\ will\\ be\\ followed\\ by\\ mastectomy\\,\\ post\\ surgical\\ radiation\\ treatments\\ and\\ maintenance\\ chemotherapy\\.\ \(0\)\
\-\ initial\\ mri\\:\ \(0\)\
\-\ \\	axial\\ gradient\\ echo\\ demonstrates\\ \\ asymmetric\\ enlargement\\ of\\ the\\ fibroglandular\\ tissue\\ of\\ the\\ left\\ breast\\,\\ most\\ prominent\\ in\\ the\\ posterior\\-lateral\\ aspect\\.\\ \\ no\\ distinct\\ masses\\ identified\\.\\ \\ three\\ distinct\\,\\ enlarged\\ and\\ rounded\\ left\\ axillary\\ lymph\\ nodes\\.\\ axial\\ post\\ gadolinium\\ gre\\ show\\ diffuse\\ heterogeneous\\ enhancement\\ throughout\\ most\\ of\\ the\\ fibroglandular\\ tissue\\ of\\ the\\ left\\ breast\\.\\ \\ the\\ axillary\\ lymph\\ nodes\\ and\\ the\\ skin\\ demonstrate\\ abnormal\\ enhancement\\.\\ sagittal\\ post\\ gadolinium\\ images\\ lateral\\ to\\ the\\ nipple\\ demonstrates\\ diffuse\\ enlargement\\ and\\ abnormal\\ enhancement\\ of\\ the\\ fibroglandular\\ tissue\\,\\ consistent\\ with\\ a\\ diffuse\\ infiltrating\\ process\\.\\ \\ no\\ discrete\\ masses\\ identified\\.\\ \\ images\\ at\\ the\\ level\\ of\\ the\\ nipple\\ demonstrate\\ significant\\ nipple\\ retraction\\.\\ \\ \\ \ \(0\)\
\-\ post\\ neoadjuvant\\ chemotherapy\\ mri\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ axial\\ gradient\\ echo\\ shows\\ near\\ resolution\\ of\\ the\\ asymmetric\\ enlargement\\ of\\ the\\ left\\ breast\\ fibroglandular\\ tissue\\.\\ \ \(0\)\
\-\ axial\\ post\\ gadolinium\\ shows\\ there\\ has\\ been\\ near\\ resolution\\ of\\ the\\ asymmetric\\ enlargement\\ of\\ the\\ left\\ breast\\ fibroglandular\\ tissue\\.\\ \\ there\\ is\\ residual\\ heterogeneous\\ enhancement\\ throughout\\ the\\ fibroglandular\\ tissue\\,\\ although\\ much\\ improved\\.\\ \\ the\\ lymph\\ nodes\\ have\\ decreased\\ in\\ size\\.\\ \\ sagittal\\ post\\ gadolinium\\ demonstate\\ the\\ nipple\\ retraction\\ has\\ resolved\\.\\ \\ the\\ skin\\ is\\ much\\ improved\\ but\\ still\\ remains\\ residually\\ thickened\\ and\\ enhanced\\.\ \(0\)\
\-\ inflammatory\\ breast\\ carcinoma\ \(0\)\
\-\ inflammatory\\ breast\\ cancer\ \(3\)\
\-\ mastitis\ \(11\)\
\-\ lymphoma\ \(373\)\
\-\ 46\\ y\\/o\\ woman\\ had\\ a\\ normal\\ screening\\ mammogram\\ in\\ june\\ 2002\\.\\ \\ in\\ november\\ 2002\\ she\\ noticed\\ left\\ axillary\\ lymphadenopathy\\,\\ but\\ an\\ excisional\\ biopsy\\ showed\\ reactive\\ lymph\\ node\\,\\ no\\ carcinoma\\.\ \(0\)\
\-\ in\\ july\\ 2003\\,\\ she\\ noticed\\ left\\ supraclavicular\\ lymphadenopathy\\.\ \(0\)\
\-\ in\\ august\\ 2003\\ patient\\ began\\ to\\ notice\\ left\\ breast\\ enlargement\\,\\ diffuse\\ skin\\ thickening\\ and\\ erythema\\,\\ and\\ upper\\ extremity\\ edema\\.\ \(0\)\
\-\ this\\ woman\\ had\\ a\\ normal\\ screening\\ mammogram\\ in\\ june\\ 2002\\.\\ \\ in\\ november\\ 2002\\ the\\ patient\\ noticed\\ left\\ axillary\\ lymphadenopathy\\.\\ \\ she\\ underwent\\ an\\ excisional\\ biopsy\\,\\ which\\ showed\\ reactive\\ lymph\\ node\\,\\ no\\ carcinoma\\.\\ \\ in\\ july\\ 2003\\,\\ she\\ noticed\\ left\\ supraclavicular\\ lymphadenopathy\\.\\ \\ in\\ august\\ 2003\\ patient\\ began\\ to\\ notice\\ left\\ breast\\ enlargement\\,\\ diffuse\\ skin\\ thickening\\ and\\ erythema\\,\\ and\\ upper\\ extremity\\ edema\\.\\ \\ a\\ mammogram\\ performed\\ at\\ that\\ time\\ showed\\ interval\\ increase\\ in\\ size\\ of\\ axillary\\ lymph\\ nodes\\ and\\ a\\ diffuse\\ increase\\ in\\ attenuation\\ of\\ left\\ breast\\ compared\\ to\\ the\\ right\\.\\ \\ yet\\ no\\ discrete\\ or\\ suspicious\\ mass\\ could\\ be\\ seen\\ in\\ either\\ side\\.\\ \\ in\\ october\\ 2003\\,\\ had\\ excisional\\ biopsy\\ of\\ left\\ supraclavicular\\ node\\ and\\ a\\ punch\\ biopsy\\ of\\ the\\ skin\\ of\\ the\\ breast\\.\\ \\ results\\ of\\ those\\ biopsies\\ showed\\ metastatic\\ cancer\\ consistent\\ with\\ breast\\ primary\\ in\\ the\\ lymph\\ node\\ and\\ invasive\\ ductal\\ carcinoma\\ with\\ involvement\\ of\\ the\\ skin\\ lymphatics\\ \\(inflammatory\\ carcinoma\\)\\ on\\ the\\ skin\\ biopsy\\.\\ \\ mri\\ was\\ performed\\ at\\ the\\ time\\ to\\ evaluate\\ for\\ primary\\ lesion\\ not\\ seen\\ on\\ mammogram\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ breast\\:\\ 0\\.38757651299259976\ \(0\)\
\-\ fibroglandular\\:\\ 0\\.2518035905745986\ \(0\)\
\-\ the\\:\\ 0\\.20633934069295057\ \(0\)\
\-\ left\\:\\ 0\\.18206566095812116\ \(0\)\
\-\ lymph\\:\\ 0\\.1815759648088889\ \(0\)\
\-\ nipple\\:\\ 0\\.17635389131846982\ \(0\)\
\-\ skin\\:\\ 0\\.1737060355577058\ \(0\)\
\-\ axillary\\:\\ 0\\.16405883731255277\ \(0\)\
\-\ enlargement\\:\\ 0\\.1534429078530307\ \(0\)\
\-\ 2003\\:\\ 0\\.15009904708658964\ \(0\)\
\-\ diffuse\\:\\ 0\\.14643668152433525\ \(0\)\
\-\ supraclavicular\\:\\ 0\\.14577702890954874\ \(0\)\
\-\ in\\:\\ 0\\.13277376684311729\ \(0\)\
\-\ noticed\\:\\ 0\\.13231860701186782\ \(0\)\
\-\ 2002\\:\\ 0\\.12769123782395528\ \(0\)\
\-\ mammogram\\:\\ 0\\.1273932575187925\ \(0\)\
\-\ excisional\\:\\ 0\\.11878857767801057\ \(0\)\
\-\ of\\:\\ 0\\.11750384558128427\ \(0\)\
\-\ biopsy\\:\\ 0\\.11691345732389054\ \(0\)\
\-\ node\\:\\ 0\\.11468702704496347\ \(0\)\
\-\ nodes\\:\\ 0\\.11335002672043125\ \(0\)\
\-\ gadolinium\\:\\ 0\\.11117975642423375\ \(0\)\
\-\ post\\:\\ 0\\.10890655544713637\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.10787197696263644\ \(0\)\
\-\ distinct\\:\\ 0\\.10621564802961922\ \(0\)\
\-\ tissue\\:\\ 0\\.10499278325909346\ \(0\)\
\-\ carcinoma\\:\\ 0\\.09976591028274553\ \(0\)\
\-\ and\\:\\ 0\\.09650199392996048\ \(0\)\
\-\ masses\\:\\ 0\\.09083764997694456\ \(0\)\
\-\ erythema\\:\\ 0\\.09055363989705334\ \(0\)\
\-\ asymmetric\\:\\ 0\\.09005942825195379\ \(0\)\
\-\ showed\\:\\ 0\\.08887485348568788\ \(0\)\
\-\ neoadjuvant\\:\\ 0\\.0878697643883593\ \(0\)\
\-\ november\\:\\ 0\\.08166376516431986\ \(0\)\
\-\ axilla\\:\\ 0\\.08099526500205374\ \(0\)\
\-\ she\\:\\ 0\\.07942862866590397\ \(0\)\
\-\ notice\\:\\ 0\\.07763065952763351\ \(0\)\
\-\ axial\\:\\ 0\\.07707486738683113\ \(0\)\
\-\ enhancement\\:\\ 0\\.0768008831401644\ \(0\)\
\-\ june\\:\\ 0\\.07669451453211615\ \(0\)\
\-\ july\\:\\ 0\\.07582777964425348\ \(0\)\
\-\ retraction\\:\\ 0\\.07426605405321328\ \(0\)\
\-\ august\\:\\ 0\\.07288851445477437\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.07105892629653515\ \(0\)\
\-\ gradient\\:\\ 0\\.07002166787941344\ \(0\)\
\-\ discrete\\:\\ 0\\.06904647253438782\ \(0\)\
\-\ inflammatory\\:\\ 0\\.06766896116920365\ \(0\)\
\-\ no\\:\\ 0\\.06508563751843145\ \(0\)\
\-\ began\\:\\ 0\\.062042739028597596\ \(0\)\
\-\ echo\\:\\ 0\\.06178847751891338\ \(0\)\
\-\ edema\\:\\ 0\\.05968613434695173\ \(0\)\
\-\ improved\\:\\ 0\\.05920386560412816\ \(0\)\
\-\ much\\:\\ 0\\.05778160102264909\ \(0\)\
\-\ reactive\\:\\ 0\\.05725783131646335\ \(0\)\
\-\ near\\:\\ 0\\.054328055432829175\ \(0\)\
\-\ screening\\:\\ 0\\.05419590070680859\ \(0\)\
\-\ resolution\\:\\ 0\\.05413037914153512\ \(0\)\
\-\ increase\\:\\ 0\\.05355663948180181\ \(0\)\
\-\ residually\\:\\ 0\\.05334652812116539\ \(0\)\
\-\ mri\\:\\ 0\\.0513689426092261\ \(0\)\
\-\ sagittal\\:\\ 0\\.051300521380500994\ \(0\)\
\-\ brawny\\:\\ 0\\.05097545558473582\ \(0\)\
\-\ congruent\\:\\ 0\\.05097545558473582\ \(0\)\
\-\ had\\:\\ 0\\.04986038180908605\ \(0\)\
\-\ distinctly\\:\\ 0\\.0492931528475257\ \(0\)\
\-\ peau\\:\\ 0\\.0492931528475257\ \(0\)\
\-\ throughout\\:\\ 0\\.04906602171199554\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.04828739517577536\ \(0\)\
\-\ extremity\\:\\ 0\\.04805190596894821\ \(0\)\
\-\ orange\\:\\ 0\\.04798825746781934\ \(0\)\
\-\ demonstate\\:\\ 0\\.04798825746781934\ \(0\)\
\-\ identified\\:\\ 0\\.0472995199879983\ \(0\)\
\-\ thickening\\:\\ 0\\.0453878433311173\ \(0\)\
\-\ lymphatics\\:\\ 0\\.04523977757388602\ \(0\)\
\-\ size\\:\\ 0\\.045173239717177266\ \(0\)\
\-\ cancer\\:\\ 0\\.04443742674284394\ \(0\)\
\-\ mastitis\\:\\ 0\\.04393488219417965\ \(0\)\
\-\ patient\\:\\ 0\\.04339858803370168\ \(0\)\
\-\ punch\\:\\ 0\\.04337752881097334\ \(0\)\
\-\ to\\:\\ 0\\.04169703485768616\ \(0\)\
\-\ maintenance\\:\\ 0\\.04156380965775008\ \(0\)\
\-\ october\\:\\ 0\\.04118640230024633\ \(0\)\
\-\ primary\\:\\ 0\\.04102300739227497\ \(0\)\
\-\ normal\\:\\ 0\\.04085940842223223\ \(0\)\
\-\ covering\\:\\ 0\\.04083188258215993\ \(0\)\
\-\ gre\\:\\ 0\\.04018145904759913\ \(0\)\
\-\ abnormal\\:\\ 0\\.04008194725955045\ \(0\)\
\-\ there\\:\\ 0\\.03981900270041976\ \(0\)\
\-\ time\\:\\ 0\\.039544125203290044\ \(0\)\
\-\ performed\\:\\ 0\\.03946927330739626\ \(0\)\
\-\ shows\\:\\ 0\\.039156391281336134\ \(0\)\
\-\ biopsies\\:\\ 0\\.03791388982212674\ \(0\)\
\-\ at\\:\\ 0\\.03779909204236658\ \(0\)\
\-\ is\\:\\ 0\\.036541139225459436\ \(0\)\
\-\ consistent\\:\\ 0\\.036174827424368644\ \(0\)\
\-\ palpated\\:\\ 0\\.035828131646900276\ \(0\)\
\-\ upper\\:\\ 0\\.03565187959173276\ \(0\)\
\-\ mastectomy\\:\\ 0\\.03540521600987307\ \(0\)\
\-\ woman\\:\\ 0\\.03474579634514431\ \(0\)\
\-\ most\\:\\ 0\\.03472091214679456\ \(0\)\
\-\ demonstrate\\:\\ 0\\.03468368484062934\ \(0\)\
\-\ treatments\\:\\ 0\\.03452323626719391\ \(0\)\
\-\ yet\\:\\ 0\\.033757011237529874\ \(0\)\
\-\ demonstrates\\:\\ 0\\.03351728238465357\ \(0\)\
\-\ right\\:\\ 0\\.033178562222764885\ \(0\)\
\-\ lateral\\:\\ 0\\.033109576433384996\ \(0\)\
\-\ but\\:\\ 0\\.032991057448696806\ \(0\)\
\-\ mobile\\:\\ 0\\.03289970572726439\ \(0\)\
\-\ infiltrating\\:\\ 0\\.032725132034880554\ \(0\)\
\-\ remains\\:\\ 0\\.03177475637326059\ \(0\)\
\-\ seen\\:\\ 0\\.03140924902607395\ \(0\)\
\-\ images\\:\\ 0\\.03086048994585845\ \(0\)\
\-\ 46\\:\\ 0\\.030647979872106747\ \(0\)\
\-\ has\\:\\ 0\\.030473824356292794\ \(0\)\
\-\ rounded\\:\\ 0\\.030354059498450985\ \(0\)\
\-\ residual\\:\\ 0\\.030354059498450985\ \(0\)\
\-\ invasive\\:\\ 0\\.030354059498450985\ \(0\)\
\-\ interval\\:\\ 0\\.030184546632351116\ \(0\)\
\-\ resolved\\:\\ 0\\.02996591240531856\ \(0\)\
\-\ discharge\\:\\ 0\\.029912507610347912\ \(0\)\
\-\ larger\\:\\ 0\\.029859586123316385\ \(0\)\
\-\ suspicious\\:\\ 0\\.029807139274847367\ \(0\)\
\-\ still\\:\\ 0\\.029551736919559243\ \(0\)\
\-\ ductal\\:\\ 0\\.0293551542271416\ \(0\)\
\-\ those\\:\\ 0\\.028544163676129622\ \(0\)\
\-\ thickened\\:\\ 0\\.02813790421772575\ \(0\)\
\-\ either\\:\\ 0\\.027576984024768023\ \(0\)\
\-\ be\\:\\ 0\\.027063924782835085\ \(0\)\
\-\ compared\\:\\ 0\\.02696799424065911\ \(0\)\
\-\ prominent\\:\\ 0\\.02627208864506166\ \(0\)\
\-\ with\\:\\ 0\\.026127567578004326\ \(0\)\
\-\ results\\:\\ 0\\.02599357008288733\ \(0\)\
\-\ evaluate\\:\\ 0\\.025939423544126986\ \(0\)\
\-\ currently\\:\\ 0\\.025624668595110357\ \(0\)\
\-\ attenuation\\:\\ 0\\.025523405728763597\ \(0\)\
\-\ an\\:\\ 0\\.02551189031413833\ \(0\)\
\-\ mass\\:\\ 0\\.025483646956263487\ \(0\)\
\-\ enhanced\\:\\ 0\\.02539924428312128\ \(0\)\
\-\ process\\:\\ 0\\.02501876641653877\ \(0\)\
\-\ could\\:\\ 0\\.02426386176951478\ \(0\)\
\-\ involvement\\:\\ 0\\.02414369758788768\ \(0\)\
\-\ palpable\\:\\ 0\\.023435138313247127\ \(0\)\
\-\ being\\:\\ 0\\.02324509018895401\ \(0\)\
\-\ or\\:\\ 0\\.023209231885557402\ \(0\)\
\-\ side\\:\\ 0\\.02304457507976461\ \(0\)\
\-\ underwent\\:\\ 0\\.02297923602676176\ \(0\)\
\-\ this\\:\\ 0\\.022924743451077395\ \(0\)\
\-\ enlarged\\:\\ 0\\.0227405178037786\ \(0\)\
\-\ although\\:\\ 0\\.02270941249423614\ \(0\)\
\-\ followed\\:\\ 0\\.02252617710440305\ \(0\)\
\-\ three\\:\\ 0\\.022392422710185704\ \(0\)\
\-\ initial\\:\\ 0\\.022377748212130906\ \(0\)\
\-\ radiation\\:\\ 0\\.0221057091901277\ \(0\)\
\-\ aspect\\:\\ 0\\.021520442701865428\ \(0\)\
\-\ will\\:\\ 0\\.02147003045512391\ \(0\)\
\-\ approximately\\:\\ 0\\.021284763078278326\ \(0\)\
\-\ show\\:\\ 0\\.021176356143381724\ \(0\)\
\-\ treated\\:\\ 0\\.020772900705365374\ \(0\)\
\-\ decreased\\:\\ 0\\.020662561877082673\ \(0\)\
\-\ level\\:\\ 0\\.020150095758754073\ \(0\)\
\-\ on\\:\\ 0\\.020149310709472974\ \(0\)\
\-\ lymphoma\\:\\ 0\\.019866689009509206\ \(0\)\
\-\ been\\:\\ 0\\.019434684526638962\ \(0\)\
\-\ significant\\:\\ 0\\.019260110834255127\ \(0\)\
\-\ than\\:\\ 0\\.018909639426753493\ \(0\)\
\-\ metastatic\\:\\ 0\\.01829513395554586\ \(0\)\
\-\ were\\:\\ 0\\.017195028406222532\ \(0\)\
\-\ have\\:\\ 0\\.016664095780638495\ \(0\)\
\-\ multiple\\:\\ 0\\.01631606999370934\ \(0\)\
\-\ surgical\\:\\ 0\\.016213022668124615\ \(0\)\
\-\ lesion\\:\\ 0\\.015992514526585774\ \(0\)\
\-\ which\\:\\ 0\\.015168164471966209\ \(0\)\
\-\ that\\:\\ 0\\.01447607328105188\ \(0\)\
\-\ by\\:\\ 0\\.01416569475874054\ \(0\)\
\-\ not\\:\\ 0\\.0131689014654226\ \(0\)\
\-\ was\\:\\ 0\\.011625554918663687\ \(0\)\
\-\ for\\:\\ 0\\.010110520443583468\ \(0\)\
